Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan, with weekly vincristine, temozolomide and vantin; to evaluate the feasibility of repetitive cycles of this chemotherapy and to estimate the response rate to this combination in children and adolescents with recurrent solid tumors and lymphomas.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oklahoma
• Treatments: Anti-Bacterial Agents; Irinotecan; Temozolomide; Vincristine

Criteria

Inclusion Criteria:

• Under age 21 years at time of study entry

• Malignant solid tumor, including CNS tumors and lymphomas

• Recurrent or refractory disease not amenable to other potentially curative therapies

• At least three weeks since last myelosuppressive chemotherapy > 6 months from allogeneic stem cell transplant

• Adequate renal and hepatic function

• Adequate peripheral blood counts unless bone marrow is involved

Exclusion Criteria:

• Patients with leukemia not eligible

• Patients with uncontrolled infection excluded

• Patients who have received more than 4 prior chemotherapies

• Patients who are receiving P450 enzyme-inducing anticonvulsants

• Patients who are receiving any other cancer chemotherapy or any other investigational agent

• Possible pregnancy will be excluded